We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $606M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
2 Miscellaneous 44.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
101
ALX Oncology
ALXO
$241M
– –
-117,817
Closed -$133K
ATXS
102
DELISTED
Astria Therapeutics
ATXS
– –
-4,000
Closed -$52.4K
BLTE
103
Belite Bio
BLTE
$6.86B
– –
-9,161
Closed -$1.47M
CDTX
104
DELISTED
Cidara Therapeutics
CDTX
– –
-3,026
Closed -$668K
DYN icon
105
Dyne Therapeutics
DYN
$3.37B
– –
-70,180
Closed -$1.37M
ELDN icon
106
Eledon Pharmaceuticals
ELDN
$215M
– –
-6,000
Closed -$9.06K
ENTA icon
107
Enanta Pharmaceuticals
ENTA
$365M
– –
-2,270
Closed -$35.8K
EXEL icon
108
Exelixis
EXEL
$14.5B
– –
-68,569
Closed -$3.01M
FOLD
109
DELISTED
Amicus Therapeutics
FOLD
– –
-82,500
Closed -$1.17M
GBIO
110
DELISTED
Generation Bio
GBIO
– –
-5,376
Closed -$30.5K
IMUX icon
111
Immunic
IMUX
$141M
– –
-15,522
Closed -$82.8K
NAMS icon
112
NewAmsterdam Pharma
NAMS
$2.62B
– –
-4,000
Closed -$140K
NRIX icon
113
Nurix Therapeutics
NRIX
$2.65B
– –
-20,000
Closed -$379K
PLRX icon
114
Pliant Therapeutics
PLRX
$70M
– –
-276,500
Closed -$337K
PRAX icon
115
Praxis Precision Medicines
PRAX
$8.67B
– –
-2,700
Closed -$796K
QURE icon
116
uniQure
QURE
$3.06B
– –
-8,742
Closed -$209K
RGC icon
117
Regencell Bioscience
RGC
$2.95B
– –
-4,400
Closed -$92.4K
RLMD icon
118
Relmada Therapeutics
RLMD
$448M
– –
-154,109
Closed -$744K
TERN
119
DELISTED
Terns Pharmaceuticals
TERN
– –
-130,413
Closed -$5.27M
VIR icon
120
Vir Biotechnology
VIR
$1.85B
– –
-200
Closed -$1.21K
VKTX icon
121
Viking Therapeutics
VKTX
$3.42B
– –
-6,000
Closed -$211K
VRDN icon
122
Viridian Therapeutics
VRDN
$2.48B
– –
-14,654
Closed -$456K
VTGN icon
123
VistaGen Therapeutics
VTGN
$10.4M
– –
-62,701
Closed -$41.5K
ZURA icon
124
Zura Bio
ZURA
$438M
– –
-166,500
Closed -$872K
ZYME icon
125
Zymeworks
ZYME
$1.97B
– –
-20,600
Closed -$542K
2 3 4
5
6

Similar funds

NPPM
North Point Portfolio Managers Orange Village, Ohio $606M AUM 20.84% 1-Year Est. Return
SCM
SKBA Capital Management San Francisco, California $606M AUM 13.33% 1-Year Est. Return
BFC
Banc Funds Company Chicago, Illinois $605M AUM 26% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
CM
Conifer Management New York $607M AUM 29.07% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.